Bangolo Ayrton, Dey Shraboni, Nagesh Vignesh Krishnan, Gumer Kabir, Avetisyan Lida, Islam Saima, Sahotra Monika, Millett Melissa, Alqinai Budoor, Pender Silvanna, Dunraj Yazmika, Syeda Habiba, Tasneem Beegum, Duran Mikel, Deugd Nicoleta De, Thakur Prasad, Weissman Simcha, Cho Christina
Department of Internal Medicine, HMH Palisades Medical Center, North Bergen, NJ 07047, USA.
Division of Bone Marrow Transplant and Cellular Therapy, John Theurer Cancer Center, Hackensack, NJ 07601, USA.
J Clin Med. 2024 Jul 25;13(15):4343. doi: 10.3390/jcm13154343.
Allogeneic stem cell transplantation (Allo-SCT) implies that a donor and a recipient are not genetically identical. Allo-SCT is used to cure a variety of conditions, including hematologic malignancies using the graft versus tumor effect, nonmalignant hematologic, immune deficiencies, and, more recently, genetic disorders and inborn errors of metabolism. Given the immunosuppressive and myeloablative nature of some of the conditioning chemotherapy regimens used during the Allo-SCT, patients are often at high risk of infection, including viral infections affecting the gastrointestinal tract, following the transplant. Furthermore, other complications such as hepatic sinusoidal obstruction syndrome (SOS) or graft-versus-host disease may occur post-transplant and may require endoscopy to assist in the diagnosis. This review will provide newer insights into the importance of endoscopic techniques in the diagnosis of post-Allo-SCT complications with a focus on safety and timing.
异基因干细胞移植(Allo-SCT)意味着供体和受体的基因不相同。Allo-SCT用于治疗多种病症,包括利用移植物抗肿瘤效应治疗血液系统恶性肿瘤、非恶性血液疾病、免疫缺陷,以及最近用于治疗遗传疾病和先天性代谢缺陷。鉴于Allo-SCT期间使用的一些预处理化疗方案具有免疫抑制和骨髓清除的性质,患者在移植后通常面临较高的感染风险,包括影响胃肠道的病毒感染。此外,移植后可能会出现其他并发症,如肝窦阻塞综合征(SOS)或移植物抗宿主病,可能需要内镜检查来辅助诊断。本综述将提供关于内镜技术在诊断Allo-SCT后并发症中的重要性的新见解,重点关注安全性和时机。